ArticleCancer2013

Volumetric tumor growth in advanced non-small cell lung cancer patients with EGFR mutations during EGFR-tyrosine kinase inhibitor therapy: developing criteria to continue therapy beyond RECIST progression.

Mizuki Nishino et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.